https://mindmedicinelaw.com/briefing/psychedelic-treatment-for-postpartum-depression-new-horizons-20260707-19950The Psychedelic Journalen2026-07-07T22:05:06.034539+00:00Psychedelic Treatment for Postpartum Depression: New Horizonspsychedelic treatment, postpartum depression, mental health, clinical trials, neuroscience, public health, serotonin pathways, FDA regulations, neuroplasticity, emotional processinghttps://mindmedicinelaw.com/briefing/compass-pathways-psilocybin-phase-iii-trial-durable-effects-20260707-19791The Psychedelic Journalen2026-07-07T15:04:37.729192+00:00Compass Pathways' Psilocybin Phase III Trial: Durable Effectspsilocybin therapy, Compass Pathways, Phase III trial, psychedelic research, mental health treatment, neuroplasticity, regulatory approval, long-term efficacy, serotonin receptors, clinical safetyhttps://mindmedicinelaw.com/briefing/tfus-in-schizophrenia-evidence-mechanisms-and-future-directions-20260706-19872The Psychedelic Journalen2026-07-07T22:05:15.773514+00:00tFUS in Schizophrenia: Evidence, Mechanisms, and Future Directionstranscranial focused ultrasound stimulation, tFUS, schizophrenia treatment, neuromodulation, clinical trials, non-invasive therapy, brain networks, neuroscience researchhttps://mindmedicinelaw.com/briefing/ketamine-s-eeg-effects-vary-in-tr-mdd-tr-ptsd-tr-ocd-20260706-19884The Psychedelic Journalen2026-07-07T22:04:31.140623+00:00Ketamine's EEG Effects Vary in TR-MDD, TR-PTSD, TR-OCDketamine, EEG, treatment-resistant depression, post-traumatic stress disorder, obsessive-compulsive disorder, personalized psychiatry, psychedelic therapy, neural mechanisms, clinical trials, psychiatric carehttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-trd-kads-study-extension-insights-20260706-19885The Psychedelic Journalen2026-07-07T22:04:16.584922+00:00Subcutaneous Ketamine for TRD: KADS Study Extension Insightssubcutaneous ketamine, treatment-resistant depression, KADS study, clinical trials, depression treatment, psychedelic research, mental health, long-term effects, safety profile, antidepressant therapyhttps://mindmedicinelaw.com/briefing/charlotte-integrates-ketamine-in-mental-health-treatment-20260706-19635The Psychedelic Journalen2026-07-06T22:04:39.965669+00:00Charlotte Integrates Ketamine in Mental Health Treatmentketamine treatment, mental health care, psychedelic therapies, depression treatment, PTSD therapy, Charlotte North Carolina, clinical trials, policy implications, patient access, treatment riskshttps://mindmedicinelaw.com/briefing/7-hydroxymitragynine-faces-schedule-i-proposal-in-u-s-20260706-19396The Psychedelic Journalen2026-07-06T15:05:37.017800+00:007-Hydroxymitragynine Faces Schedule I Proposal in U.S.7-hydroxymitragynine, Schedule I, kratom, Controlled Substances Act, public comments, OASH, drug policy, research restrictions, plant medicine, U.S. regulationhttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-depression-efficacy-and-safety-insights-20260706-19466The Psychedelic Journalen2026-07-06T15:05:25.122874+00:00Subcutaneous Ketamine for Depression: Efficacy and Safety Insightssubcutaneous ketamine, treatment-resistant depression, ketamine safety, ketamine efficacy, clinical trials, mental health treatment, depression therapies, psychiatric research, NMDA receptor antagonisthttps://mindmedicinelaw.com/briefing/oregon-s-proposed-psilocybin-fee-increases-impacts-and-implications-20260706-19476The Psychedelic Journalen2026-07-06T15:05:14.639147+00:00Oregon's Proposed Psilocybin Fee Increases: Impacts and Implicationsoregon psilocybin fees, psilocybin regulation, psychedelic industry, oregon policy changes, psilocybin business impact, therapeutic psilocybin, psilocybin market dynamics, regulatory framework, psilocybin legalization, psychedelic therapyhttps://mindmedicinelaw.com/briefing/dea-s-temporary-scheduling-of-mitragynine-derivatives-implications-20260706-19391The Psychedelic Journalen2026-07-06T15:05:02.263164+00:00DEA's Temporary Scheduling of Mitragynine Derivatives: ImplicationsDEA, mitragynine derivatives, Schedule I, psychedelic research, regulatory compliance, controlled substances, market impact, legal risks, research challenges, substance schedulinghttps://mindmedicinelaw.com/briefing/dea-moves-to-schedule-7-hydroxymitragynine-as-schedule-i-20260706-19392The Psychedelic Journalen2026-07-06T15:04:52.556079+00:00DEA Moves to Schedule 7-Hydroxymitragynine as Schedule IDEA, 7-hydroxymitragynine, Schedule I, controlled substances, psychedelic research, botanical industry, regulatory controls, substance abuse, research implications, market disruptionhttps://mindmedicinelaw.com/briefing/psilocybin-mdma-efficacy-for-ptsd-trd-in-systematic-review-20260705-19840The Psychedelic Journalen2026-07-07T22:04:40.723595+00:00Psilocybin & MDMA: Efficacy for PTSD & TRD in Systematic Reviewpsilocybin, MDMA, PTSD, treatment-resistant depression, systematic review, clinical trials, psychedelic therapy, mental health, Phase 3 trials, regulatory implicationshttps://mindmedicinelaw.com/briefing/psilocybin-s-clinical-potential-and-legal-reevaluation-20260705-19521The Psychedelic Journalen2026-07-06T22:04:49.878841+00:00Psilocybin's Clinical Potential and Legal Reevaluationpsilocybin, psilocybe mushrooms, depression treatment, psychiatric disorders, serotonergic agonist, mental health protocols, schedule I drug, therapeutic potential, legal status, clinical trialshttps://mindmedicinelaw.com/briefing/trump-s-endorsement-of-psychedelic-therapy-policy-implications-20260705-19477The Psychedelic Journalen2026-07-06T15:05:49.731566+00:00Trump's Endorsement of Psychedelic Therapy: Policy Implicationspsychedelic therapy, Trump endorsement, federal policy, research funding, bipartisan support, mental health treatment, FDA breakthrough therapy, clinical trials, political polarization, ethical concernshttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-reducing-alcohol-relapse-preclinical-insights-20260704-19458The Psychedelic Journalen2026-07-07T15:05:26.450292+00:00Ayahuasca's Potential in Reducing Alcohol Relapse: Preclinical Insightsayahuasca, alcohol relapse, preclinical research, neurochemistry, oxidative stress, psychedelic-assisted therapy, alcohol use disorder, clinical trials, psychedelic research, addiction treatmenthttps://mindmedicinelaw.com/briefing/integrating-gender-affirming-care-in-ed-treatment-for-trans-people-20260704-19557The Psychedelic Journalen2026-07-06T22:05:09.443843+00:00Integrating Gender-Affirming Care in ED Treatment for Trans Peopleeating disorders, transgender health, gender-affirming care, mental health disparities, systematic review, clinical practice, policy implications, minority stressors, gender dysphoria, healthcare equityhttps://mindmedicinelaw.com/briefing/psychedelic-therapy-for-ibs-emerging-research-and-implications-20260704-19558The Psychedelic Journalen2026-07-06T22:05:00.121560+00:00Psychedelic Therapy for IBS: Emerging Research and Implicationsbrain-gut axis, irritable bowel syndrome, psychedelic-assisted therapy, personalized medicine, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/oxytocin-and-mindfulness-therapy-a-new-approach-for-ssd-20260704-19541The Psychedelic Journalen2026-07-06T22:04:20.925207+00:00Oxytocin and Mindfulness Therapy: A New Approach for SSDoxytocin, mindfulness-based group therapy, schizophrenia spectrum disorders, negative symptoms, clinical trials, mental health treatmenthttps://mindmedicinelaw.com/briefing/proposed-framework-for-ibogaine-medical-development-20260703-19462The Psychedelic Journalen2026-07-07T15:05:36.950183+00:00Proposed Framework for Ibogaine Medical Developmentibogaine development, psychoactive substances, clinical trials, safety and efficacy, regulatory pathways, neurotransmitter systems, addiction treatment, psychopharmacology, cardiac toxicity, psychedelic medicinehttps://mindmedicinelaw.com/briefing/oregon-s-regulatory-merger-psilocybin-and-marijuana-oversight-20260703-19794The Psychedelic Journalen2026-07-07T15:04:50.723486+00:00Oregon's Regulatory Merger: Psilocybin and Marijuana Oversightoregon psilocybin regulation, marijuana oversight merger, regulatory consolidation, psilocybin fee hike, oregon health authority, psychedelic industry policy, business compliance costs, clinical trial implications, public perception of psychedelics, state regulatory frameworkshttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-for-treating-eating-disorders-20260702-19787The Psychedelic Journalen2026-07-07T15:04:59.733016+00:00Psilocybin's Potential for Treating Eating Disorderspsilocybin, eating disorders, transdiagnostic treatment, clinical guidelines, mental health, psychedelic research, serotonin modulation, treatment protocols, psychopathology, clinical trialshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-aud-new-clinical-trial-20260701-19858The Psychedelic Journalen2026-07-07T22:04:53.768037+00:00MDMA-Assisted Therapy for PTSD & AUD: New Clinical TrialMDMA-assisted therapy, PTSD treatment, alcohol use disorder, clinical trial, integrated exposure therapy, mental health researchhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-brain-circuits-long-term-effects-modeled-20260701-19788The Psychedelic Journalen2026-07-07T15:05:08.928913+00:00Psilocybin's Impact on Brain Circuits: Long-Term Effects Modeledpsilocybin, brain circuits, fronto-striatal-thalamic connectivity, neuropsychiatric disorders, clinical trials, therapeutic applications, neuroscience, psychedelic research, long-term effects, mental healthhttps://mindmedicinelaw.com/briefing/psychedelics-and-autism-mechanisms-and-ethical-challenges-20260623-19626The Psychedelic Journalen2026-07-06T22:04:31.051227+00:00Psychedelics and Autism: Mechanisms and Ethical Challengespsychedelics, autism spectrum disorder, clinical trials, neuroscience, ethical challenges, serotonin receptors, neuroplasticity, informed consent, translational evidence, treatment protocols